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1 The use of iterative research strategies, positive controls and pharmacodynamic  
effect biomarkers, can optimize early drug development far beyond mere assessment  
of pharmacokinetics, safety and tolerability in healthy volunteers (this thesis). 
2 An important reason for the lack of progress in schizophrenia treatment, is the absence  
of adequate animal models (Conn & Roth, Neuropsychopharmacology 2008; 33: 2048-60).  
Models in healthy volunteers can provide useful alternatives (this thesis), and could  
be used to improve existing or develop new animal models. 
3 thc administration can be a useful pharmacological model for psychotic effects  
in healthy volunteers (this thesis). 
4 The scopolamine challenge model is a widely used cholinergic cognitive impairment  
model in animals and humans, but its value is uncertain. This uncertainty is largely  
reduced by determination of concentration-effect relationships (this thesis). 
5 The visual effects of glycine reuptake inhibitors are specific for this drug class (this thesis). 
6 All antipsychotics are based on the same antidopaminergic mechanism of action  
as the first neuroleptic chlorpromazine, discovered in 1952. 
7 About 2600 compounds with about 210 mechanisms of action have been in development  
for the treatment of schizophrenia in the past years. Nonetheless, the only compound  
that was registered for this condition in the past ten years was an active metabolite of  
a much older drug.
8 Drug development in schizophrenia has been even less successful than in other  
psychiatric disease areas (Agid Y et al., Nat Rev Drug Discov 2007; 6:189-201; Conn & Roth, 
Neuropsychopharmacology 2008; 33: 2048-60; Carpenter & Koenig, Neuropsychopharmacology  
2008; 33: 2061-79). An increasing number of large pharmaceutical companies have  
abandoned this field. This worsens the prospects for patients to get more effective  
treatments (van Gerven & Cohen, Br J Clin Pharmacol 2011; 72: 1-5).
9 Schizophrenia is too complex and multidimensional for a ‘magic bullet’ therapeutic  
strategy. A ‘magic shotgun’ strategy may be more successful, where each patient is  
treated with an individualized drug combination, aimed at his or her personal multi- 
dimensional disease profile (Gray & Roth, Mol Psychiatry 2007; 12: 904-22).
10 Not knowledge or enthusiasm, but patience is the most important quality to finish  
a PhD in the end. 
11 A system of fines would encourage researchers to publish their findings faster.
12 Although educational differences between physicians and pharmacists are necessary  
for their contributions to health care, some joint training will improve collaboration  
and mutual understanding. 
13 It is good to have an end to journey toward; but it is the journey that matters, in the end.  
(Ernest Hemingway, 1899-1961)
